The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

npsp.com

Founded Year

1986

Stage

Acq - P2P | Acquired

Valuation

$0000 

Revenue

$0000 

About Nps Pharmaceuticals

NPS Pharmaceuticals is developing specialty therapeutics for gastrointestinal and endocrine disorders. The company is currently advancing two late-stage programs: GATTEX (teduglutide) is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome and in preclinical development for the GI Mucositis and Necrotizing Enterocolitis indications and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is in Phase 2 clinical development as a hormone therapy for hypoparathyroidism. NPS complements its internal programs with strategic partnerships, which include Amgen, GlaxoSmithKline, Kirin, and Nycomed.n

Nps Pharmaceuticals Headquarter Location

550 Hills Drive 3rd Floor

Bedminster, New Jersey, 07921,

United States

908-450-5300

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Nps Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nps Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Nps Pharmaceuticals Patents

Nps Pharmaceuticals has filed 60 patents.

The 3 most popular patent topics include:

  • Graphene
  • Nanomaterials
  • Monolayers
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/24/2018

3/16/2021

Chemical bonding, Cooling technology, Graphene, Atmospheric thermodynamics, Nanomaterials

Grant

Application Date

2/24/2018

Grant Date

3/16/2021

Title

Related Topics

Chemical bonding, Cooling technology, Graphene, Atmospheric thermodynamics, Nanomaterials

Status

Grant

Latest Nps Pharmaceuticals News

07:00 ET Omega Therapeutics Expands Board of Directors with Appointment of Luke Beshar

Jun 23, 2021

Former Chief Financial Officer of NPS Pharmaceuticals and Cambrex Corporation News provided by Share this article Share this article CAMBRIDGE, Mass., June 23, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. ("Omega"), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harness the power of epigenetics and pioneer novel DNA-sequence-based targets and develop a new class of mRNA-encoded programmable epigenetic medicines, today announced the appointment of Luke Beshar to its Board of Directors. Mr. Beshar is a corporate finance veteran and most recently served as Executive Vice President and Chief Financial Officer at NPS Pharmaceuticals, Inc., through its acquisition by Shire PLC. "Luke is a seasoned financial executive with over 35 years of company development and financial management experience at various high-growth public and private life science companies," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "His deep expertise in strategic planning and finance will be an asset as we expand the therapeutic reach of the OMEGA Epigenomic Programming™ platform and advance our first programs to the clinic." "I am pleased to welcome Luke to the Board at this pivotal stage of Omega's development," said Noubar Afeyan, Ph.D., Co-founder and Chairman of the Board for Omega Therapeutics and Founder and Chief Executive Officer of Flagship Pioneering. "I look forward to working closely with Luke to help Omega advance several pipeline assets toward the clinic." "Omega is pioneering a new class of programmable mRNA-encoded therapeutics, Omega Epigenomic Controllers™, to treat and cure a wide range of serious diseases," said Mr. Beshar. "I am honored to join the Board during this key period of growth for the Company and to collaborate with the management team on executing their goal of transforming human medicine in the service of patients." During his tenure at NPS Pharmaceuticals, Mr. Beshar oversaw financial management, investor relations, technical operations, information technology, quality assurance, project management, contracts & outsourcing, and facilities. Prior to this role, he served as Executive Vice President, Strategy and Corporate Development and Chief Financial Officer of Cambrex Corporation and as Chief Financial Officer of Dendrite International. Earlier in his career, Mr. Beshar held various general and financial management positions of increasing responsibility. He began his career at Arthur Anderson & Co. and is a Certified Public Accountant. Currently, Mr. Beshar serves on the board of directors of Protara Therapeutics, REGENXBIO Inc. and Trillium Therapeutics. He holds a B.A. degree in accounting and financial management from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia. About Omega Therapeutics Omega Therapeutics is a privately held, development-stage biotechnology company pioneering a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to transform human medicine. The OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that systematically controls every aspect of an organism's life from cell genesis, to growth and differentiation. The OMEGA platform has identified thousands of novel DNA-sequence-based epigenomic targets within Insulated Genomic Domains (IGDs), referred to as EpiZips™. IGDs represent the three-dimensional, distinct, and evolutionarily conserved architecture of the genome, and are the fundamental structural and functional units of gene control and cell differentiation. They act as the "control room" of biology. The OMEGA platform examines alterations in IGDs leading to aberrant gene expression, a cause of most disease. It then leverages its database of EpiZips to identify appropriate intervention points within the IGDs and rationally designs biologically engineered, modular, and programmable mRNA-encoded epigenetic medicines, called Omega Epigenomic Controllers™, to target EpiZips for Precision Genomic Control™. With its computation- and data-first approach, Omega Therapeutics is currently advancing a broad pipeline of programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases. Omega Therapeutics was founded by Flagship Pioneering in 2017. For more information, visit omegatherapeutics.com , or follow us on Twitter  and LinkedIn . Investor contact:

  • When was Nps Pharmaceuticals founded?

    Nps Pharmaceuticals was founded in 1986.

  • Where is Nps Pharmaceuticals's headquarters?

    Nps Pharmaceuticals's headquarters is located at 550 Hills Drive, Bedminster.

  • What is Nps Pharmaceuticals's latest funding round?

    Nps Pharmaceuticals's latest funding round is Acq - P2P.

  • Who are the investors of Nps Pharmaceuticals?

    Investors of Nps Pharmaceuticals include Shire, Putnam Investments, Ashton Partners, Falcon Point Capital, The Great-West Life Assurance Company and 19 more.

  • Who are Nps Pharmaceuticals's competitors?

    Competitors of Nps Pharmaceuticals include Immunomic Therapeutics, Ambrx, Viracta Therapeutics, Adastra Pharmaceuticals, Crown Bioscience International and 15 more.

You May Also Like

I
IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.

N
NanoFluence Health

Plans to develop and market food and beverage applications complemented with high-efficacy and high-quality nutraceutical supplements and pharmaceutical systems. Products will feature and incorporate high-concentration EPA & DHA omega-3 oils and calcium complexation ingredients to treat specific health conditions. The highest priority target conditions are disease states resulting from deficiencies in EPA & DHA essential fatty acids and calcium such as ADHD, high-cholesterol, and osteoporosis. NanoFluence has demonstrated a range of food and beverage products featuring omega-3 oils and is conducting formulation and optimization work to reduce both the effective dosage level and the time to realize noticeable gains in treating target conditions.

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

I
InteKrin Therapeutics

InteKrin Therapeutics, Inc. is a privately-held clinical stage biopharmaceutical company based in Los Altos, California developing therapeutics for diabetes, obesity and metabolic disorders. The company was founded in 2005 by Denny Lanfear, a former Vice President and Officer of Amgen, and clinical endocrinologist Christos Mantzoros, M.D., DSc, FACP, FACE, Associate Professor of Medicine at Harvard Medical School. InteKrin's Scientific Advisory Board includes veterans from several successful biopharma organizations, internationally recognized experts in nuclear receptors and metabolism as well as top scientists formerly with the Food and Drug Administration. Its lead product, INT131, is a novel SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator) which is in Phase II clinical trials for diabetes. The company focuses on high value therapeutics in addressing unmet medical needs. To learn more about InteKrin, visit www.intekrin.com

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

N
NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.